


EXHIBIT C

NEURONTIN[®]
(gabapentin)

U.S. Market Update
February 2002

*Nancy Mancini
April 9, 2002*


AED Market Trends




In January 2002, Neurontin's NRx share increased to 24.5% from 24.2% in December 2001.

In January 2002, overall TRx volume in the AED market increased by 4% and NRx volume increased by 10% versus December 2001.

Compared to January 2001, overall TRxs and NRxs in the AED market increased 11% and 12%, respectively.



Source: IMS




NEURONTIN
(gabapentin)

In January 2002, Neurontin's NRx share increased to 24.5% from 24.2% in December 2001.


In January 2002, overall TRx volume in the AED market increased by 4% and NRx volume increased by 10% versus December 2001.

Compared to January 2001, overall TRxs and NRxs in the AED market increased 11% and 12%, respectively.



Neurontin Prescription Overview

Neurontin Monthly NRx/TRx Volume (000)




Neurontin recorded 1.4MM total Rx's in January 2002 (up 5% from December 2001) with 640,000 new Rx's (up 11%) and 740,000 refill Rx's (unchanged compared to 12/01).


In January 2002, Neurontin's monthly total Rx's increased 19% and new Rx's increased 15% compared with January 2001.

The 800mg and 600mg tablets accounted for approximately 15% of the new Rx's for Neurontin in January 2002.

Neurontin Prescriptions by Month



Source: IMS




2/01 3/01 4/01 5/01 6/01 7/01 8/01 9/01 10/01 11/01 12/01 1/02 2/02

NEURONTIN®
(gabapentin)

Neurontin recorded 1.4MM total Rx's in January 2002 (up 5% from December 2001) with 640,000 new Rx's (up 11%) and 740,000 refill Rx's (unchanged compared to 12/01).


In January 2002, Neurontin's monthly total Rx's increased 19% and new Rx's increased 15% compared with January 2001.

The 800mg and 600mg tablets accounted for approximately 15% of the new Rx's for Neurontin in January 2002.



Neurontin NRx and TRx by Physician Specialty

Neurontin NRx Volume by Specialty




Compared to January 2001, Neurontin NRx volume in January 2002 increased 25% among PCPs, 13% among anesth/rehab/ortho/rheum specialists, 5% among neurologists and 1% among psychiatrists. Compared to January 2001, Neurontin Rx volume in 1/02 increased 29% among PCPs, 16% among anesth/rehab/ortho/rheum specialists, 6% among neurologists and 5% among psychiatrists.

PCPs continue to be the leading prescribers of Neurontin, accounting for 33% of new Rx's (up 3% from January 2001) and 36% of total Rx's (up 3% from in January 2001).

Psychiatrists are the next leading prescribers, accounting for 20% of new Rx's (down from 23% in January 2001) and 17% of total Rx's (down from 19% in January 2001).

The percentage of Neurontin new Rx's accounted for by Anesth/rehab/ortho/rheumspecialists remained constant at 14% and Neurologists share decreased to 12% (from 13% in January 2001).

Neurontin TRx Volume by Specialty



Source: IMS


NEURONTIN®
(Gabapentin)

Compared to January 2001, Neurontin NRx volume in January 2002 increased 25% among PCPs, 13% among anesth/rehab/ortho/rheum specialists, 5% among neurologists and 1% among psychiatrists. Compared to January 2001, Neurontin total Rx's volume in 1/02 increased 29% among PCPs, 16% among anesth/rehab/ortho/rheum specialists, 6% among neurologists and 5% among psychiatrists.

PCPs continue to be the leading prescribers of Neurontin, accounting for 33% of new Rx's (up 3% from January 2001) and 36% of total Rx's (up 3% from in January 2001.)


Psychiatrists are the next leading prescribers, accounting for 20% of new Rx's (down from 23% in January 2001) and 17% of total Rx's (down from 19% in January 2001).

The percentage of Neurontin new Rx's accounted for by Aesth/rehab/ortho/rheumspecialists remained constant at 14% and Neurologists share decreased to 12% (from 13% in January 2001).




Epilepsy Uses in AED Market

Drug Uses for Epilepsy by Product



Share of Epilepsy Drug Uses by Product



These charts present physician-intended drug uses for epilepsy broken out by product.


In 4Q01, the first generation agents account for 60% of drug uses for epilepsy, with phenytoin accounting for 32% of uses, carbamazepine 15% of uses and Depakote/ene/ER 13% of uses.

Neurontin's share of physician epilepsy uses increased to 5% in 4Q01 (from 3% in 4Q00).

Compared to prior year, Lamiclal and Keppra share of epilepsy uses remained steady at 4% and 3%, respectively, while Topamax's share of epilepsy uses increased to 4% (from 3%).

Source: Scott-Levin


NEURONTIN
(gabapentin)



Concomitant Use in Epilepsy

MAT February 2001/2002


Drug Uses for Epilepsy



The monotherapy agents, Depakote/ene/ER, phenytoin, carbamazepine and Trileptal, are used alone 56% of the time to treat epilepsy.

Of the adjunctive therapy agents, Lamictal is used as a monotherapy agent 38% of the time and Neuro is used as monotherapy 32% of the time.

Among the adjunctive agents, Lamictal was the most often utilized adjunctive agent over the past year. Neurontin's uses both as a monotherapy and as an adjunctive therapy have decreased since last year, and 8%, respectively. Lamictal uses as a monotherapy agent increased 55% over prior year, while its as an adjunctive therapy agent decreased 9% versus last year.



MAT 2/02 Share	Depakote/ene/ER	Total phenytoin	Total carbamazepine	Trileptal	Neurontin	Topamax	Lamictal	Topamax	Neurontin	Trileptal	Topamax	Lamictal	Keppra	Zonegran
Used Alone	57.8%	68.1%	60.9%	65.0%	31.5%	26.1%	37.7%	31.9%	42.0%	12.1%	11.7%	17.8%	—	—
Depakote/ene/ER	—	—	—	1.3%	17.1%	16.2%	—	—	—	22.0%	13.7%	10.0%	—	—
Total Phenytoin	11.2%	3.3%	8.7%	8.1%	29.4%	28.4%	—	—	—	17.1%	13.2%	24.7%	13.4%	—
Total carbamazepine	12.8%	4.4%	0.6%	4.2%	17.1%	17.7%	—	—	—	4.2%	5.3%	3.7%	3.4%	—
Trileptal	0.2%	0.4%	0.4%	0.5%	—	—	—	—	—	—	—	—	—	—
Neurontin	5.3%	3.7%	4.2%	—	—	—	—	5.8%	—	—	—	—	—	—
Topamax	3.8%	2.1%	3.3%	7.1%	4.4%	—	—	—	—	—	4.4%	—	—	—
Lamictal	3.9%	1.8%	3.4%	12.5%	3.9%	6.1%	—	—	—	—	—	—	—	—
Keppra	2.7%	0.9%	4.5%	5.9%	4.1%	11.2%	—	—	—	—	—	—	—	—
Zonegran	1.7%	0.4%	1.0%	2.4%	0.7%	0.8%	—	—	—	—	—	—	—	—

NEURONTIN
(gabapentin)


Drug Uses for Epilepsy

monotherapy agents, Depakote/ene/ER, phenytoin, carbamazepine and Trileptal, are used alone over the time to treat epilepsy.

As an adjunctive therapy agents, Lamictal is used as a monotherapy agent 38% of the time and Neurontin as monotherapy 32% of the time.


As adjunctive agents, Lamictal was the most often utilized adjunctive agent over the past year.

John's uses both as a monotherapy and as an adjunctive therapy have decreased since last year, 23% respectively. Lamictal uses as a monotherapy agent increased 55% over prior year, while its use adjunctive therapy agent decreased 9% versus last year.



Neurontin: Physician Prescribing Behavior

Percent of Physicians Prescribing Neurontin by Specialty



43% of all neurologists prescribed Neurontin in December 2001 (up from 41% in December 2000).


Psychiatrists are the next leading specialty with 30% prescribing Neurontin in December 2001 (up from 28% in December 2000).

18% of all PCPs prescribed Neurontin in December 2001 (up from 14% in 12/00).


Among Neurontin prescribers, PCPs average number of NRxs increased to 3.2 in December 2001 (up 3% from 12/00), while the average number of NRxs decreased for Neurologists and Psychiatrists by 11% and 6%, respectively over the same period.

Across all prescribers, the average number of Neurontin TRxs was 6.9 of which 4.4 are new prescriptions. Neurologists are the heaviest prescribers averaging 18.7 TRxs and 8.4 NRxs per month.


Average # of Neurontin New Rx's/Month Among Prescribers



Average Neurontin NRxs vs. TRxs Among Prescribers




AED Promotion Summary



Depakote/ene/ER was the most heavily detailed product with 9,000 details December 2001, followed by Topamax and Lamictal (4,000 details, each Neurontin recorded 2,000 details).


Depakote/ene/ER has the highest share of samples by brand with a 39% share (63,000 samples) in December 2001. Topamax was the next most sample product with a 17% share (27,000 samples). Neurontin recorded 22,000 samples with a 14% share.



NEURONTIN®
(gabapentin)


Depakote/lene/ER was the most heavily detailed product with 9,000 details in December 2001, followed by Topamax and Lamictal (4,000 details, each). Neurontin recorded 2,000 details.

Depakote/lene/ER has the highest share of samples by brand with a 39% share (63,000 samples) in December 2001. Topamax was the next most sampled product with a 17% share (27,000 samples). Neurontin recorded 22,000 samples with a 14% share.




Neurontin Channels/Method of Payment

Neurontin Channels (% of Dollars)



86% of Neurontin sales are sold through retail and/or mail order channels.

Method of Payment for Neurontin (% of Rx's)




Source: IMS

NEURONTIN
(gabapentin)

86% of Neurontin sales are sold through retail and/or mail order channels.

The method of payment for Neurontin has remained stable over the past 12 months with third-party payers reimbursing over 72% of Neurontin new Rx's.

Unique Projected Patient Counts



NDC unique patient-level data indicated that the cumulative number of Neurontin patients was 7.7 million as of December 2001. This number represents a patient who had a prescription filled for Neurontin between January 1996 to December 2001. During the full year 2001, the number of new patients filling a Neurontin Rx was 2.3 million, a 16% increase over 2000.

Source: NDC Physician-Level Data

NEURONTIN
(Gabapentin)

Neurontin

Tegamox
Lamictal
Trileptal
Keppra
Zonegran

Neurontin patients was 7.7 million as of December 2001. This number represents a
6 to December 2001. During the full year 2001, the number of new patients filling a

EPILEPSY MARKET-NRX VOLUME

EPILEPSY MARKET-CUSTOM MONTHLY DATA

Date	Neuronin	Depakote/ enoxER	Total phenytoin		Total carbamazepine		Total Topamax		Lamictal		Keppra		Zomegran		Gabitril		Felbatol		All Other AEDs		Total			
			2/00	422	388	270	230	43	41	44	8	0	5	0	5	2	607	2010	654	2180	2/00	471	417	
3/00	440	440	440	440	383	261	222	49	41	8	1	0	4	2	2	654	2180	598	2010	5/00	492	417		
4/00	492	492	492	492	283	242	242	58	44	8	4	0	5	2	2	650	2226	641	2164	6/00	488	401		
5/00	488	488	488	488	274	232	60	44	10	6	1	5	2	2	641	2164	7/00	475	382	265	223	59	42	
6/00	505	505	505	505	386	256	216	74	45	17	9	3	4	2	2	631	2163	7/00	470	382	265	223	59	42
7/00	558	558	558	558	416	275	233	86	50	20	11	4	5	2	2	620	2089	8/00	519	406	277	234	68	46
8/00	518	518	518	518	383	250	211	83	47	20	11	4	5	2	2	607	2010	654	2180	9/00	497	379		
9/00	578	578	578	578	428	274	228	68	44	13	8	2	4	2	2	633	2134	10/00	531	403	269	229	75	47
10/00	547	547	547	547	400	267	215	94	50	26	13	5	6	2	2	661	2249	11/00	517	388	257	216	74	45
11/00	585	585	585	585	422	268	222	102	52	30	15	7	8	2	2	684	2397	12/00	560	403	251	212	75	46
12/00	592	592	592	592	404	259	221	105	51	32	15	7	8	2	2	658	2304	1/01	572	404	259	221	107	53
1/01	602	602	602	602	424	265	229	118	57	33	17	9	11	2	2	623	2157	2/01	518	383	250	211	83	47
3/01	551	551	551	551	389	244	203	110	52	38	17	9	10	2	2	656	2281	4/01	547	400	267	215	94	50
6/01	626	626	626	626	431	264	223	119	59	45	20	11	13	2	2	733	2546	11/01	592	408	253	209	114	58
12/01	579	579	579	579	398	250	211	113	59	43	20	11	12	2	2	694	2420	1/02	640	428	271	232	128	65
1/02	586	586	586	586	396	243	203	125	60	53	22	13	15	2	2	745	2615	2/02	586	396	243	203	125	60

EPILEPSY MARKET-NRX SHARE

Date	Neuronin	Depakote/ enoxER	Total phenytoin		Total carbamazepine		Total Topamax		Lamictal		Keppra		Zomegran		Gabitril		Felbatol		All Other AEDs		Total	
			2/00	21%	19%	13%	11%	2%	2%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
3/00	22%	19%	13%	11%	2%	2%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
4/00	22%	19%	13%	11%	3%	2%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
5/00	19%	19%	13%	11%	3%	2%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
6/00	23%	18%	13%	11%	3%	2%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
7/00	23%	18%	13%	11%	3%	2%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
8/00	23%	18%	12%	10%	3%	2%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
9/00	23%	18%	12%	10%	3%	2%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
10/00	24%	18%	12%	10%	3%	2%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
11/00	18%	18%	12%	10%	4%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
12/00	23%	18%	12%	10%	3%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
1/01	24%	18%	12%	10%	4%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
2/01	24%	18%	12%	10%	4%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
3/01	24%	18%	12%	10%	4%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
4/01	24%	18%	12%	10%	4%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
5/01	24%	17%	11%	9%	5%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
6/01	24%	17%	11%	9%	5%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
7/01	24%	17%	11%	9%	5%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
8/01	24%	17%	11%	9%	5%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
9/01	24%	17%	11%	9%	5%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
10/01	25%	17%	10%	9%	5%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
11/01	24%	17%	10%	9%	5%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
12/01	24%	17%	10%	9%	5%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
1/02	24%	16%	10%	9%	5%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
2/02	24%	16%	10%	9%	5%	2%	1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Epilepsy Market Custom Monthly Data

Epilepsy Market Custom Monthly Data													
TRX VOLUME	Date	Depot/enter	Total	carbamazepine	Topamax	Lamictal	Topamax	Keppea	Zonispran	Gabril	Felbatol	All Other AEDs	Total
Neuronin	2/00	831	827	819	636	85	98	9	9	0	13	7	1154
	3/00	923	886	870	677	97	106	12	1	0	12	7	1245
	4/00	578	830	817	636	97	102	15	5	0	13	8	4833
	5/00	977	902	861	683	112	110	10	1	0	12	7	1161
	6/00	978	873	850	680	116	108	8	1	12	7	8	4553
	7/00	987	864	857	656	119	108	20	11	2	12	7	1235
	8/00	1049	895	871	670	131	113	24	14	3	12	7	4866
	9/00	1016	846	827	641	110	105	26	16	4	12	7	5082
	10/00	1088	892	862	666	144	117	31	20	6	12	8	1266
	11/00	1073	865	833	640	145	115	33	21	7	12	7	4872
	12/00	1093	881	848	649	153	119	37	23	8	12	7	5006
	1/01	1160	925	876	673	168	124	41	27	9	13	7	5307
	2/01	1067	843	792	606	158	114	40	26	9	12	7	4872
	3/01	1202	933	878	664	184	130	49	31	11	13	7	5447
	4/01	1159	892	833	633	184	125	50	32	12	14	7	5234
	5/01	1229	931	861	656	198	132	57	37	14	15	7	5488
	6/01	1198	894	826	626	202	129	60	38	15	16	7	5307
	7/01	1237	913	848	643	212	135	65	41	17	18	7	5476
	8/01	1279	938	857	651	227	140	73	44	18	20	7	5300
	9/01	1204	878	805	606	218	133	73	45	20	19	7	5475
	10/01	1339	953	864	653	238	146	85	51	23	22	7	5815
	11/01	1235	918	850	624	232	144	88	52	24	22	7	5611
	12/01	1318	926	841	633	240	152	94	56	24	24	7	5307
	1/02	1380	964	857	650	259	159	103	60	28	26	7	5427
	2/02	1262	876	774	584	246	146	99	56	23	25	6	5945
	Share of previous month	23%	16%	14%	11%	4%	3%	2%	1%	0%	0%	0%	100%
	Share of sales month	23%	16%	14%	11%	5%	3%	2%	1%	0%	0%	24%	100%
Neuronin Prescriptions by Month													
New Rx	Feb-01	518	586	549	676	1057	1252	18%					
Refill Rx													
Total													
Neuronin Rx by Strength													
Feb-01			Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02
Oral Solution													
100 MG	24%	23%	24%	24%	24%	24%	24%	24%	24%	24%	24%	24%	24%
300 MG	52%	52%	52%	52%	52%	51%	51%	51%	51%	51%	51%	51%	51%
400 MG	12%	12%	12%	11%	11%	11%	11%	11%	11%	11%	11%	11%	11%
800 MG	9%	9%	9%	9%	9%	9%	9%	10%	10%	10%	10%	10%	11%
800 MG	4%	4%	4%	4%	4%	4%	4%	4%	4%	4%	5%	5%	5%
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Neuronin Rx by Strength													
Feb-01			Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02
100 MG	231	260	249	286	258	265	277	259	280	284	284	284	284
300 MG	564	633	609	645	627	644	664	625	693	671	680	670	649
400 MG	138	153	147	153	148	152	155	143	158	151	154	159	144
600 MG	90	105	104	112	112	113	124	120	134	133	139	146	136
800 MG	43	50	49	53	53	56	59	56	63	62	64	69	63
TOTAL	1057	1202	1159	1229	1198	1237	1279	1203	1339	1295	1318	1380	1262
Neuronin Rx by Specialty													
Feb-01			Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02
NPS/PAs	8	9	9	9	9	9	9	10	9	10	10	10	10
Neuro	64	61	65	61	61	62	65	59	68	64	62	67	62
Anesth/Rehab/													
Otto/Rheum	65	72	68	74	66	71	75	67	77	73	71	79	71
Total Others	83	93	89	95	91	94	101	92	104	99	97	105	96
Psych	102	113	105	111	105	106	108	100	112	105	102	111	101
PCP (G/F/P/DC/IM)	134	152	147	160	154	158	168	156	176	164	182	186	166
NPS/PAs	451	503	479	514	489	500	523	483	547	519	506	555	506
Neuro	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
Anesth/Rehab/	13%	13%	13%	13%	13%	12%	12%	12%	12%	12%	12%	12%	12%
Otto/Rheum													
Total Others	18%	18%	18%	18%	19%	19%	19%	19%	19%	19%	19%	19%	14%
Psych	23%	22%	22%	22%	22%	21%	21%	21%	21%	20%	20%	20%	20%
PCP (G/F/P/DC/IM)	30%	31%	31%	31%	31%	31%	31%	31%	32%	32%	32%	33%	33%
Neuronin Rx by Specialty													
Feb-01			Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02
NPS/PAs	14	16	16	17	17	17	17	17	17	20	20	21	20
Neuro	165	161	169	162	167	170	176	160	176	170	174	177	162

		Epilepsy Market Custom Monthly Data					
Anesth/Rehab/		124	128	133	123	137	132
Ortho/Rheum		121	130	178	184	181	195
Total Others		178	172	183	188	201	195
Patch	169	169	179	188	184	187	192
PCP (GPP/DO)(M)	343	343	334	359	354	384	364
						406	396
						404	421
							388

Epilepsy Market Custom Monthly Data

Epilepsy Diagnoses Volume by Brand

	3Q99	4Q99	1Q00	2Q00	3Q00	4Q00	1Q01	2Q01	3Q01	4Q01
All Other AEDs	403	436	472	454	513	490	411	357	363	370
Trileptal	—	—	11	28	28	26	27	40	28	39
Total carbamazepine	362	368	311	377	351	384	331	310	320	249
Total phenytoin	633	636	583	625	637	580	619	639	539	526
Depakote/Depakene/ER	231	241	245	257	226	190	263	287	198	217
Keppea	—	—	—	17	31	60	49	37	72	51
Lamictal	76	78	68	76	74	81	71	73	68	72
Tosumax	29	63	56	55	52	54	55	60	41	70
Neuronitin	86	99	120	108	72	57	83	88	67	74
Epilepsy Diagnoses Share by Brand										
3Q99	4Q99	1Q00	2Q00	3Q00	4Q00	1Q01	2Q01	3Q01	4Q01	
All Other AEDs	21%	23%	25%	23%	26%	22%	22%	15%	21%	22%
Trileptal	—	—	1%	1%	1%	2%	2%	2%	2%	2%
Total carbamazepine	19%	19%	17%	19%	18%	21%	17%	18%	19%	15%
Total phenytoin	37%	33%	31%	31%	31%	32%	32%	34%	32%	32%
Depakote/Depakene/ER	12%	13%	13%	13%	11%	10%	14%	15%	12%	13%
Keppea	—	—	—	1%	2%	3%	3%	4%	3%	3%
Lamictal	4%	4%	4%	4%	4%	4%	4%	4%	4%	4%
Tosumax	2%	3%	3%	3%	3%	3%	3%	3%	2%	4%
Neuronitin	5%	5%	6%	5%	4%	3%	4%	5%	4%	5%
Concomitant Use in Epilepsy - MAT 2002										
Volume	496	519	539	489	514	Total	Trileptal	Neuronitin	Topamax	Lamictal
mono/ER	496	519	539	539	514	carbamazepine	carbamazepine	carbamazepine	carbamazepine	Keppea
Adjunctive 2001	—	—	—	—	—	—	—	—	—	Zonegran
Adjunctive 2002	—	—	—	—	—	—	—	—	—	—
MAT 2002 Share										
Used Alone	57.8%	60.7%	60.9%	65.0%	60.9%	65.0%	60.9%	31.9%	31.9%	30.0%
Depakote/Depakene/ER	—	4.5%	10.1%	1.3%	11.1%	16.2%	12.1%	11.7%	11.7%	10.8%
Total carbamazepine	11.2%	3.3%	8.7%	8.1%	29.4%	20.0%	13.7%	10.0%	10.0%	10.8%
Trileptal	12.8%	4.4%	0.6%	4.2%	17.1%	17.1%	13.2%	24.7%	13.2%	13.4%
Neuronitin	0.2%	0.3%	0.5%	—	—	—	4.2%	5.3%	3.5%	3.4%
Topamax	3.8%	2.1%	3.3%	7.1%	4.4%	—	5.8%	3.7%	5.5%	2.3%
Lamictal	3.9%	3.4%	3.4%	12.5%	3.9%	6.1%	4.4%	11.4%	5.5%	2.0%
Keppea	2.1%	0.9%	4.5%	5.5%	4.1%	11.2%	11.7%	16.3%	16.2%	—
Zonegran	1.1%	0.4%	1.0%	2.4%	0.7%	0.8%	4.9%	—	—	4.5%
Percent of Physicians Prescribing Neuronitin by Specialty										
May-00	May-00	Apr-00	May-00	Jun-00	Jul-00	Aug-00	Sep-00	Oct-00	Nov-00	Dec-00
Anesth/Rehab/Ortho/Rheum	10%	10%	11%	10%	11%	11%	11%	12%	12%	12%
Neuro	40%	40%	41%	41%	41%	41%	41%	43%	43%	43%
NPs/PAs	0%	0%	0%	0%	0%	1%	1%	1%	1%	1%
Total Others	3%	3%	3%	3%	3%	3%	3%	3%	3%	3%
PCP (GPs/FPs/DOs/M)	12%	12%	12%	13%	13%	14%	14%	16%	16%	17%
Psych	26%	26%	26%	27%	27%	27%	28%	30%	30%	30%
Ave # of Neuronitin New Prescribers										
Mar-00	Mar-00	Apr-00	May-00	Jun-00	Jul-00	Aug-00	Sep-00	Oct-00	Nov-00	Dec-00
Anesth/Rehab/Ortho/Rheum	6.9	6.6	7.1	6.7	7.1	6.8	6.9	6.8	7.4	7.4
Neuro	9.0	8.7	8.9	9.0	8.5	8.7	8.6	8.5	8.9	8.9
NPs/PAs	3.1	3.1	3.0	3.2	3.0	3.3	3.2	3.5	3.3	3.4
Total Others	2.7	2.7	2.6	2.7	2.6	2.6	2.6	2.5	2.7	2.7
PCP (GPs/FPs/DOs/M)	3.0	3.0	3.1	3.1	3.0	3.1	3.0	3.0	3.4	3.4
Psych	6.9	6.7	6.8	7.0	6.7	7.1	7.0	7.1	7.2	7.2
Total Prescribers	4.7	4.5	4.6	4.7	4.5	4.6	4.5	4.6	4.7	4.5
Ave # of Neuronitin New Prescribers (Jan-02)										
Anesth/Rehab/Ortho/Rheum	7.2	10.4	—	—	—	—	—	—	—	—
Neuro	8.7	18.5	—	—	—	—	—	—	—	—
NPs/PAs	3.2	4.0	—	—	—	—	—	—	—	—
Total Others	2.7	3.6	—	—	—	—	—	—	—	—
PCP (GPs/FPs/DOs/M)	3.3	5.2	—	—	—	—	—	—	—	—
Psych	6.9	10.0	—	—	—	—	—	—	—	—
Total Prescribers	4.5	6.8	—	—	—	—	—	—	—	—
Ave # of Neuronitin New vs. TRx# Among Prescribers (Jan-02)										
Anesth/Rehab/Ortho/Rheum	7.2	10.4	—	—	—	—	—	—	—	—
Neuro	8.7	18.5	—	—	—	—	—	—	—	—
NPs/PAs	3.2	4.0	—	—	—	—	—	—	—	—
Total Others	2.7	3.6	—	—	—	—	—	—	—	—
PCP (GPs/FPs/DOs/M)	3.3	5.2	—	—	—	—	—	—	—	—
Psych	6.9	10.0	—	—	—	—	—	—	—	—
Total Prescribers	4.5	6.8	—	—	—	—	—	—	—	—
Ave # of Neuronitin New vs. TRx# Month										
NPs/Month	—	—	—	—	—	—	—	—	—	—
TRx#Month	—	—	—	—	—	—	—	—	—	—

Epilepsy Market Custom Monthly Data

EPILEPSY MARKET-Samples		Neuronitin												Neuronitin Method of Payment											
Date	Neuronitin	Total phenytoin	Total carbamazepine	Total Topamax	Lamictal	Topamax	Keppea	Zonisgran	Gabitril	All Other AEDs	Total Market	FEB/01	MAT FEB/02	Third Party	Medicaid	Cash	FEB/01	MAT FEB/02	Third Party	Medicaid	Cash				
2/0/00	47	133	—	58	9	14	—	—	—	0	355	71%	72%	17%	17%	11%	74	73	72	73	72				
3/0/00	110	240	—	13	25	30	—	—	—	2	477	—	—	—	—	—	12	12	12	14	13				
4/0/00	118	185	—	—	15	27	3	—	—	7	1	385	—	—	—	—	1	1	1	3	3				
5/0/00	33	258	—	—	15	35	33	19	3	3	393	—	—	—	—	—	1	1	1	1	1				
6/0/00	68	84	—	—	9	45	19	2	5	1	238	—	—	—	—	—	1	1	1	1	1				
7/0/00	132	95	—	—	18	24	11	13	—	1	294	—	—	—	—	—	1	1	1	1	1				
8/0/00	174	73	—	5	26	—	—	19	—	—	295	—	—	—	—	—	1	1	1	1	1				
9/0/00	9	71	—	—	11	3	33	14	2	—	143	—	—	—	—	—	0	0	0	0	0				
10/0/00	26	38	—	—	12	7	53	29	14	2	190	—	—	—	—	—	3	3	3	3	3				
11/0/00	13	94	—	40	25	1	33	22	10	—	1	239	—	—	—	—	—	1	1	1	1	1			
12/0/00	9	115	0	23	3	0	6	—	—	2	158	—	—	—	—	—	1	1	1	1	1				
1/0/01	25	131	2	22	22	—	39	7	6	—	238	—	—	—	—	—	6	6	6	6	6				
2/0/01	36	58	0	32	1	26	8	10	2	0	173	—	—	—	—	—	0	0	0	0	0				
3/0/01	7	87	0	6	4	9	18	0	22	0	153	—	—	—	—	—	0	0	0	0	0				
4/0/01	144	55	—	26	—	30	2	9	12	3	281	—	—	—	—	—	0	0	0	0	0				
5/0/01	7	72	0	8	24	12	27	—	12	32	0	194	—	—	—	—	—	0	0	0	0	0			
6/0/01	0	73	0	0	31	6	20	0	5	9	0	144	—	—	—	—	—	0	0	0	0	0			
7/0/01	6	37	—	23	2	34	13	17	5	0	137	—	—	—	—	—	0	0	0	0	0				
8/0/01	142	136	—	19	16	90	—	20	12	4	439	—	—	—	—	—	0	0	0	0	0				
9/0/01	24	122	0	0	25	0	34	4	12	23	0	244	—	—	—	—	—	0	0	0	0	0			
10/01	0	140	0	0	44	15	0	0	16	7	0	222	—	—	—	—	—	0	0	0	0	0			
11/01	7	62	0	0	42	0	10	4	1	26	0	151	—	—	—	—	—	0	0	0	0	0			
12/01	22	63	0	0	27	6	13	9	19	3	0	162	—	—	—	—	—	0	0	0	0	0			
1/02	11	82	0	0	36	7	65	57	16	52	351	—	—	—	—	—	0	0	0	0	0				
2/02	33%	23%	0%	10%	2%	19%	5%	15%	7%	100%	—	—	—	—	—	—	0	0	0	0	0				
Share of states month	3%	3%	0%	0%	0%	0%	0%	0%	0%	0%	0	—	—	—	—	—	0	0	0	0	0				
Neuronitin Channels (% of Dollars)	Mar-00	Apr-00	May-00	Jun-00	Jul-00	Aug-00	Sep-00	Oct-00	Nov-00	Dec-00	Jan-01	Feb-01	Mar-01	Apr-01	May-01	Jun-01	Jul-01	Aug-01	Sep-01	Oct-01	Nov-01	Dec-01	Jan-02		
Retail Pharmacy	75	74	74	74	74	74	74	74	73	73	72	74	74	73	73	73	74	74	73	73	73	73	72		
Mail Order	12	12	12	13	12	12	12	12	13	12	13	13	13	13	13	13	13	13	13	13	13	13	13		
LTC	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5		
Non-Fed Hosp	4	4	3	3	3	3	3	3	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3		
Clinics	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
Fed Facilities	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
HMO	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
All Other	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		

Unique Projected Patient Counts	Keppra	Lamotriptan	Topamax	Triptol	Zonegran
Neurotin	240,264	42,061	46,380	42,061	
896	277,198	48,155	50,155	48,155	
936	313,023	50,155	52,155	50,155	
1096	355,160	54,779	56,779	54,779	
1136	392,658	59,210	61,210	59,210	
1296	429,544	63,784	65,784	63,784	
157	459,985	68,575	70,575	68,575	
2197	511,768	73,782	75,782	73,782	
2397	559,281	79,356	81,356	79,356	
4197	808,322	84,239	86,239	84,239	
5197	657,752	88,422	90,422	88,422	
6197	705,181	93,502	95,502	93,502	
7197	765,716	98,712	100,712	98,712	
8197	818,287	103,382	105,382	103,382	
9197	873,440	108,115	110,115	108,115	
10197	936,141	113,572	115,572	113,572	
11197	982,831	118,704	120,704	118,704	
12197	1,051,506	124,244	126,244	124,244	
198	1,109,264	129,488	131,488	129,488	
2198	1,170,816	134,230	136,230	134,230	
2398	1,238,723	140,247	142,247	140,247	
4198	1,309,848	146,128	148,128	146,128	
5198	1,382,266	151,901	153,901	151,901	
6198	1,459,404	158,147	160,147	158,147	
7198	1,528,365	164,334	166,334	164,334	
6198	1,620,784	171,044	173,044	171,044	
9198	1,705,337	177,013	179,013	177,013	
10198	1,794,384	183,965	186,965	183,965	
11198	1,885,692	190,745	192,745	190,745	
12198	1,984,358	198,070	200,070	198,070	
1198	2,084,041	205,085	207,085	205,085	
2199	2,181,831	211,938	213,938	211,938	
3199	2,318,413	220,380	222,380	220,380	
4199	2,443,068	228,484	230,484	228,484	
5199	2,563,324	236,856	238,856	236,856	
6199	2,686,664	245,061	247,061	245,061	
7199	2,821,831	253,372	255,372	253,372	
8199	2,956,044	263,034	265,034	263,034	
9199	3,088,251	272,455	274,455	272,455	
10199	3,225,927	281,561	283,561	281,561	
11199	3,360,356	290,503	292,503	290,503	
12199	3,494,350	299,867	301,867	299,867	
1100	3,630,678	308,185	310,185	308,185	
2100	3,779,395	316,896	318,896	316,896	
3100	3,944,394	328,898	330,898	328,898	
4100	4,101,150	1,120	338,231	219,536	
5100	4,268,673	248,850	385,924	248,850	
6100	4,437,308	7,633	358,177	259,094	
7100	4,602,995	11,254	388,107	278,232	
8100	4,778,336	15,001	378,416	300,731	
9100	4,945,086	20,195	388,218	323,799	
10100	5,118,33	24,850	398,416	348,094	
11100	5,285,196	28,246	408,200	377,843	
12100	5,447,123	32,226	418,254	397,937	
1101	5,621,552	37,197	428,888	423,870	
2101	5,785,690	41,721	438,987	450,287	
3101	5,947,126	47,434	450,287	482,206	
4101	6,167,712	52,543	461,702	513,201	
5101	6,367,486	60,234	474,339	548,455	
6101	6,558,790	68,917	486,440	585,236	
7101	6,748,475	73,047	498,742	621,321	
8101	6,950,390	75,976	512,523	660,439	
9101	7,132,776	88,202	525,221	695,846	
10101	7,335,385	92,811	539,296	732,066	
11101	7,516,704	100,934	552,835	767,170	
12101	7,705,547	108,421	566,438	804,428	
1102	7,914,208	116,364	581,153	841,710	